All In Biotech

Drug Trial Radar · NCT05690646

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery During COVID-19 Pandemics: A Prospective, Randomized Controlled, Multicenter Trial

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 491 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

491

Actual

Start

Jan 28, 2023

Primary completion

Mar 24, 2023

Study completion Aug 1, 2024

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jan 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery during covid-19 pandemics (the pep trial) is a multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications after cardiac surgery.

Conditions

  • Cardiac Surgery

Interventions

  • Nirmatrelvir/ritonavirDrug

    nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days

  • Ursodeoxycholic acidDrug

    ursodeoxycholic acid 15mg/kg/day bid for5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MACCETime frame: 30 days after surgery or during hospitalization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.